389 related articles for article (PubMed ID: 21923598)
1. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
Zineh I; Pacanowski MA
Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
[TBL] [Abstract][Full Text] [Related]
2. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
Lesko LJ; Zineh I
Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
[TBL] [Abstract][Full Text] [Related]
3. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
4. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
5. Regulatory approval for new pharmacogenomic tests: a comparative overview.
Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
[TBL] [Abstract][Full Text] [Related]
6. Regulatory agency consideration of pharmacogenomics.
Pendergast MK
Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
[TBL] [Abstract][Full Text] [Related]
7. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
Lesko LJ; Woodcock J
Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
[TBL] [Abstract][Full Text] [Related]
8. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
Phillips KA; Van Bebber SL
Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
10. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
11. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
12. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
Goodsaid F; Frueh FW
Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
[TBL] [Abstract][Full Text] [Related]
13. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
14. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics: history, barriers, and regulatory solutions.
Blankstein S
Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
[TBL] [Abstract][Full Text] [Related]
16. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
[TBL] [Abstract][Full Text] [Related]
18. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
[TBL] [Abstract][Full Text] [Related]
19. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
Mandry T
Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and the concept of individualized medicine.
Shastry BS
Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
